Basics of immunooncology and immunotherapy in oncology
Authors:
Open Access
- 7 October 2022
- journal article
- review article
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 9,p. 129-139
Abstract
The purpose of the review is to present an analysis of current literature data on tumor immunology, effector mechanisms of antitumor immunity, and prospects for the development of new immunotherapeutic approaches to cancer treatment. Immunological surveillance is the intellectual basis of the idea of tumor immunology. No one doubts the role of immunological mechanisms in protection against tumors. However, tumor cells have a variety of mechanisms that allow them to avoid the action of immune surveillance factors. Some of these factors are aimed at making it difficult to recognize foreign components in the tumor and trigger immune processes. Other mechanisms prevent the implementation of effector mechanisms. Understanding the mechanisms of immunological escape may suggest immune therapy mechanisms that will be widely applicable to different types of cancer.Keywords
This publication has 109 references indexed in Scilit:
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaNew England Journal of Medicine, 2013
- Modulation of GITR for cancer immunotherapyCurrent Opinion in Immunology, 2012
- Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of IdoNature Medicine, 2011
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responsesJournal of Experimental Medicine, 2011
- Mechanisms for T cell receptor triggeringNature Reviews Immunology, 2010
- Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cellsProceedings of the National Academy of Sciences, 2010
- OX40 is required for regulatory T cell–mediated control of colitisJournal of Experimental Medicine, 2010
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cellsJournal of Experimental Medicine, 2009
- OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosisJournal of Experimental Medicine, 2009
- BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1Nature Immunology, 2003